Dr. Falk Pharma and Allianthera Partner to Advance ATB102 for Ulcerative Colitis

• Dr. Falk Pharma and Allianthera have entered a strategic partnership to develop ATB102, a novel AhR agonist, for moderate-to-severe ulcerative colitis.

• The agreement includes global licensing rights (excluding Greater China), co-development, and contract manufacturing through Dr. Falk’s subsidiary, Losan Pharma.

Dr. Falk Pharma GmbH has signed a strategic agreement with Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. and its affiliate Allianthera Boston, Inc. to co-develop ATB102, a novel aryl hydrocarbon receptor (AhR) agonist, for the treatment of inflammatory bowel disease (IBD), with a focus on refractory moderate-to-severe ulcerative colitis.

ATB102, currently in Phase 1 clinical trials in the United States, is a gut-enriched small molecule designed to target inflammation and mucosal damage within the gastrointestinal tract. Under the agreement, Dr. Falk Pharma secures exclusive global rights to license, manufacture, and commercialise ATB102 outside Mainland China, Hong Kong, Macau, and Taiwan. Allianthera will receive an upfront signing fee, milestone payments, and tiered royalties.

The partnership includes development of an innovative colonic-release formulation through Losan Pharma GmbH, Dr. Falk Pharma’s fully owned contract development and manufacturing organisation (CDMO). This formulation will complement the existing immediate-release version of ATB102.

Yuanhua Ding, CEO of Allianthera, stated, “We are delighted to join forces with Dr. Falk Pharma, who has deep expertise in formulation and clinical development.”

The collaboration aims to accelerate the advancement of ATB102 and broaden Dr. Falk Pharma’s pipeline in digestive and inflammatory diseases, leveraging both companies’ scientific and clinical expertise.